Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2106 participants.

Also called NCT04135989

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,106 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04135989
Other papers using this trial's data
  • Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The PARTHENOPE Randomized Trial Journal of the American College of Cardiology, 2025-12-09 DOI, PubMed 40892607
  • Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2025-01-06 DOI, PubMed 39773824, PMC11684330 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04135989. Randomized; single masking; primary purpose treatment. Start 2020-01-01 (actual); primary completion 2021-10-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
Acronym
PARTHENOPE
Condition
Acute Coronary Syndrome
Condition
Chronic Coronary Syndrome
Intervention (Device)
Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.
Intervention (Device)
Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.
Intervention (Drug)
Personalized DAPT duration
Intervention (Drug)
Standard DAPT duration
Lead sponsor
Federico II University (class: other)
Collaborator
AdvicePharma Group (class: not stated)

Record details

Record id
cardio:ct-nct04135989
Content hash
3471095eeda45ada4fbfae1d74a96822d432b1b350da67bd3b1d21fcfd148471